Tiger Brokers

  • Quotes
  • Invest
  • Pricing
  • Download
  • Rewards
  • Help
  • TigerAI
  • Institution
    • Wealth and asset manager
    • Proprietary trading institutions
    • Introducing brokers
    • Third-party service provider
    • Esop
  • About
    • About us
    • Newsroom
    • Awards
  • LOGIN
  • SIGN UP
HK StockDetailed Quotes
Provided by Tiger Trade Technology Pte. Ltd.

IMMUNEONCO-B

3.340
-0.060-1.76%
Volume:436.60K
Turnover:1.47M
Market Cap:1.43B
PE:-5.40
High:3.435
Open:3.400
Low:3.320
Close:3.400
52wk High:16.800
52wk Low:2.800
Shares:429.00M
HK Float Shares:418.00M
Volume Ratio:0.90
T/O Rate:0.10%
Dividend:- -
Dividend Rate:- -
EPS(LYR):-0.619
ROE:-40.11%
ROA:-14.74%
PB:1.96
PE(LYR):-5.40
PS:8.32

Loading ...

OverviewCompanyNewsFilings

IMMUNEONCO-B Reports Fiscal Year Performance: Revenue Jumps 108.09% to 154 Million Yuan

Stock News
·
Mar 25

ImmuneOnco Posts FY-2025 Loss Narrowing to RMB219 Million; Revenue Doubles on Up-fronts and Milestones

Bulletin Express
·
Mar 25

ImmuneOnco Biopharmaceuticals Shanghai Inc - FY Loss Attributable RMB218.6 Mln

THOMSON REUTERS
·
Mar 25

ImmuneOnco Biopharmaceuticals FY2025; revenue rises to CNY 154 million due to Axion payments

Reuters
·
Mar 25

ImmuneOnco Biopharmaceuticals FY2025 operating loss narrows 30.74% to RMB219 million; revenue jumps 108.23% to RMB154 million due to Axion Bio payments

Reuters
·
Mar 25

IMMUNEONCO-B (01541) Completes Enrollment of 133 Patients for Interim Analysis in Phase III Trial of IMM01 (Tidapaxic) as First-Line Treatment for Chronic Myelomonocytic Leukemia

Stock News
·
Mar 23

ImmuneOnco completes enrollment of 133 patients for interim analysis in Phase III IMM01 CMML trial

Reuters
·
Mar 23

IMMUNEONCO-B (01541) Surges Over 10% Following Phase II Clinical Trial Approval for IMM0306 in Primary Membranous Nephropathy

Stock News
·
Mar 18

Analyst Rate

Hold
Buy
0.00%
Hold
100.00%
Sell
0.00%

Corporate Actions

Financial Report Announcement
Aug 26, 2026
Financial Report Announcement
Mar 25, 2026
Financial Report Announcement
Aug 26, 2025
Financial Report Announcement
Mar 25, 2025 Post-Mkt
Financial Report Announcement
Aug 26, 2024 Post-Mkt

Dividend History

no data

No relevant data is available

Valuation Analysis

-5.27
Current
-11.81
Sector Average
87.60%
Historical Percentile
P/E[TTM]
+1 STD
Average
-1 STD
Current
-5.27
Maximum
-4.23
+1 STD
-4.82
Minimum
-29.80
-1 STD
-18.81
Average
-11.81

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10
     
     
     
     
Company Name:
Tiger Trade Technology Pte. Ltd.
Email Address:
dpo@itiger.com
User Agreement|Privacy Policy

Copyright © Tiger Trade Technology Pte. Ltd.

Product offerings in different jurisdictions may vary.

Information contained on this website is general in nature and does not take into account of your investment objectives, financial situation and specific needs. It should not be regarded as an offer to sell, asolicitation to buy, a recommendation or endorsement for any financial product, nor does it constitute an investment forecast, investment return commitments, investment suggestions or other practical operating opinions. Information contained on this website is for reference only and past performance should not be construed as future performance. Investment involves risks. Before you make an investment decision, you should carefully judge and screen whether the information contained on this website is appropriate for your needs, goals and circumstances.

We strive but cannot guarantee the accuracy, completeness, reliability and timeliness of all information on this website, and we are not responsible for any losses caused by the use of or reliance on relevant information.

The products and services offered on the website are subject to applicable laws, regulations and relevant agreements. Please carefully read and agree to the agreements before using our products and services.